Raphael Landovitz MD MSc

HIV/AIDS Medicine

UCLA Center for Clinical AIDS Research & Education

1399 S. Roxbury Dr, Suite 100Los Angeles, CA 90035
Phone+1 310-557-2273
Fax+1 310-557-3450

Dr. Landovitz is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Landovitz's full profile Already have an account?

Summary

Dr. Raphael Landovitz is an infectious disease specialist in Los Angeles, CA and is affiliated with multiple hospitals in the area, including Ronald Reagan UCLA Medical Center and UCLA Medical Center-Santa Monica. He received his medical degree from Harvard Medical School and has been in practice 20 years. He also speaks multiple languages, including Spanish and Vietnamese. He specializes in hiv/aids medicine and is experienced in hiv/aids and sexually transmitted infections.

Education & Training

Mass General Brigham/Massachusetts General Hospital/Brigham and Women's HospitalFellowship, Infectious Disease, 1999 - 2001
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 1997 - 1999
Mass General Brigham/Brigham and Women's HospitalInternship, Internal Medicine, 1996 - 1997
Harvard Medical SchoolClass of 1996

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 2006 - 2028
VT State Medical License 2016 - 2026
MA State Medical License 1998 - 2007
American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2016-2017
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2016-2017

Clinical Trials

Comparative Study of Three NNRTI-Sparing HAART Regimens
COMPLETED
PHASE3
Interventions for HIV Negative Men and Women Who Have High-risk Suspected Exposure to HIV
COMPLETED
PHASE2
A Demonstration Project to Add Pre- or Post-exposure Prophylaxis to Combination HIV Prevention Services
COMPLETED
PHASE4

Publications & Presentations

PubMed

Providing the Best Infectious Diseases and Primary Care to Our Patients With HIV: Time for Delivery Models to Evolve.
Christopher J Graber, Raphael J Landovitz, Westyn Branch-Elliman
Clinical Infectious Diseases. 2026-07-23
PrEP as a "Hidden Message": The Impact of Partner Dynamics on Oral PrEP Adherence Among Cisgender Women in Serodiscordant Relationships.
Thupten D Phuntsog, Jamila K Stockman, K Rivet Amico, Ryan Kofron, Sheldon Morris
AIDS and Behavior. 2026-06-01
Prospective HIV RNA screening with long-acting cabotegravir pre-exposure prophylaxis in HPTN 083.
Raphael J Landovitz, Jessica M Fogel, Fei Gao, Brett Hanscom, Estelle Piwowar-Manning
Clinical Infectious Diseases. 2026-04-27

Journal Articles

Safety, Tolerability, and Pharmacokinetics of Long-Acting Injectable Cabotegravir in Low-Risk HIV-Uninfected Individuals: HPTN 077, a Phase 2a Randomized Controlled Trial
Susan H Eshleman, Joseph J Eron, Raphael J Landovitz, Myron S Cohen, Jeremy Sugarman, Mark A Marzinke, Craig W Hendrix, PLoS One
Antiretroviral Concentrations in Hair Strongly Predict Virologic Response in a Large HIV Treatment-Naive Clinical Trial
Raphael J Landovitz, Judith S Currier, Clinical Infectious Diseases
Emergence of Integrase Resistance Mutations During Initial Therapy Containing Dolutegravir
Jennifer A Fulcher, Raphael J Landovitz, Clinical Infectious Diseases

Press Mentions

UCLA’s HIV Prevention and Treatment Center Receives $7.5 Million Grant from NIHMarch 17th, 2022
Breakthrough HIV Reported in Injectable PrEP Trial; Experts Say Drug Still Very EffectiveFebruary 16th, 2022
Cabotegravir Bests TDF-FTC for HIV Prevention in Those at RiskAugust 13th, 2021

Grant Support

UCLA AIDS Prevention and Treatment Clinical Trials UnitUNIVERSITY OF CALIFORNIA LOS ANGELES2007–2027
HIV Prevention Trials Network Leadership and Operations CenterFAMILY HEALTH INTERNATIONAL2006–2027
Center for HIV Identification, Prevention and Treatment ServicesUNIVERSITY OF CALIFORNIA LOS ANGELES1997–2026
Center for HIV Identification, Prevention and Treatment ServicesUNIVERSITY OF CALIFORNIA LOS ANGELES1997–2026
Center for HIV Identification, Prevention and Treatment ServicesUNIVERSITY OF CALIFORNIA LOS ANGELES1997–2026